A Phase 3 interventional study of Inhaled Insulin and Subcutaneous Insulin in Asthma and Diabetes Mellitus, sponsored by Pfizer. Completed at 102 sites in 5 countries. Open to participants aged 18 Years to 77 Years. Per ClinicalTrials.gov, last updated 2010-06-02.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Asthma by Pfizer — 4 open to participants now, 4 under way, 2 of them phase 3. Asthma · Pfizer.
Among the 24 studies in Asthma by Pfizer, this one is the 3rd largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2003, is one of 3 in phase 3, and was the 1st registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →4 of the 24 studies in Asthma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Puerto Rico
Ages 12–80
Pfizer · Sites in United States, Japan
Ages 12–80
Pfizer · Sites in United States, Belgium
Ages 18–65 · Healthy volunteers
Pfizer · Sites in United States, Argentina, Belgium and 12 more countries
Ages 18–75
By country, each count listing its studies:
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 77 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 288 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 48 across the 20 interventional studies, 20 across the 3 observational. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Asthma by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06977581PfizerA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | 2027-03-08 |
| NCT07660731PfizerA Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma | 2027-03-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Asthma by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Asthma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Inhaled Insulin
Drug: Subcutaneous Insulin
Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
Annualized Rate of Change for Forced Expiratory Volume in 1 Second (FEV1)
Annualized rates of change (slope throughout time from baseline to end of study\[visit\]) for forced expiratory volume in 1 second (FEV1) (liters per year \[L/yr\]) measured 30 minutes following the administration of albuterol.
Time frame: Weeks -3, -2, -1, 1, 2, 3, 4, 6, 12, 18, 26, 39, and 52
Annualized Rate of Change for Hemoglobin-adjusted Carbon Monoxide Diffusion Capacity (DLco)
Annualized rates of change (slope throughout time from baseline to end of study\[visit\]) for hemoglobin-adjusted carbon monoxide diffusion capacity (DLco)in milliliters per minute/millimeters of mercury/year (ml/min/mmHg/yr) measured 30 minutes following the administration of albuterol.
Time frame: Weeks -3, -2, -1, 1, 2, 3, 4, 6, 12, 18, 26, 39, and 52
Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second (FEV1)
Change from Baseline at each visit in post-bronchodilator forced expiratory volume in one second (FEV1). FEV1 was measured in liters (L) 30 minutes following the administration of albuterol. Change from baseline: mean FEV1 (L) at observation minus baseline value.
Time frame: Baseline through Week 52 Last Observation Carried Forward (LOCF)
Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco)
Carbon Monoxide Diffusing Capacity (DLco) measured in milliters/minutes/millimeters of mercury (mL/min/mmHg) 30 minutes following the administration of albuterol. Change from Baseline: mean DLco (mL/min/mmHg) at observation minus baseline value.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1)
Change from Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) at each visit. FEV1 was measured in liters (L) before the administration of albuterol. Change from baseline: mean FEV1 (L) at observation minus mean baseline value.
Time frame: Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Change From Baseline in Pre-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco)
Change From Baseline in Pre-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco) measured in milliters/minutes/millimeters of mercury (mL/min/mmHg): change = DLco at observation minus DLco at Baseline.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation carried Forward (LOCF)
Change From Baseline in Pre-Insulin Forced Expiratory Volume in One Second (FEV1)
Change from Baseline in Pre-Insulin Forced Expiratory Volume in one second (FEV1) measured in liters (L): change = FEV1 at observation minus FEV1 at Baseline.
Time frame: Baseline, Week 9, Week 51, Week 51 Last Observation Carried Forward
Change From Baseline in Pre-Insulin Carbon Monoxide Diffusing Capacity (DLco)
Change From Baseline in Pre-Insulin Carbon Monoxide Diffusing Capacity (DLco) measured in milliters/minutes/millimeters of mercury (mL/min/mmHg): change = DLco at observation minus DLco at Baseline.
Time frame: Baseline, Week 9, Week 51, Week 51 Last Observation Carried Forward (LOCF)
Change From Baseline in Post-bronchodilator Forced Vital Capacity (FVC)
Change from baseline in Post-bronchodilator Forced Vital Capacity (FVC) measured in liters (L) 30 minutes following the administration of albuterol: change = FVC at observation minus FVC at Baseline.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Bronchodilator Responsiveness as Determined by the Change in Forced Expiratory Volume in 1 Second (FEV1) Pre-albuterol and 30 Minutes Post-albuterol
Responsiveness was the percent change from the forced expiratory volume in 1 second (FEV1) value before bronchodilator use to the FEV1 value 30 minutes after bronchodilator use, operationally defined as \[(post-bronchodilator FEV1 minus pre-bronchodilator FEV1 divided by pre-bronchodilator FEV1\] multiplied by 100.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52
Percent Predicted and Percent Change From Baseline in Post-Bronchdilator Forced Expiratory Volume in One Second (FEV1)
Percent predicted change from Baseline in post-bronchodilator forced expiratory volume in one second (FEV1) measured in liters (L): National Health and Nutrition Examination Survey (NHANES III) reference standard. Percent change from Baseline in post-bronchdilator FEV1 measured in liters (L): (observed value minus Baseline value) divided by Baseline value \*100%.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Change From Baseline in Insulin Dose Responsiveness for Forced Expiratory Volume in One Second (FEV1) Measured 10 and 60 Minutes After the First Daily Dose of Insulin
Change from Baseline in Insulin Dose Responsiveness for Forced Expiratory Volume in one second (FEV1) measured 10 and 60 minutes after the first daily dose of insulin. Insulin dose responsiveness = the difference between FEV1 value following a dose of insulin and FEV1 value before a dose of insulin, operationally defined as the post dose FEV1 value minus predose FEV1 value.
Time frame: Baseline, Week 9, Week 51
Percent Predicted and Percent Change From Baseline in 10 Minute and 60 Minute Post-Insulin Forced Expiratory Volume in One Second (FEV1)
Percent predicted change from Baseline in 10 Minute and 60 Minute post-insulin forced expiratory volume in one second (FEV1) measured in liters (L): National Health and Nutrition Examination Survey (NHANES III) reference standard. Percent change from Baseline in FEV1 measured in liters (L) 10 and 60 Minutes post-insulin. Percent change = (value at observation minus Baseline value) divided by Baseline value \*100%.
Time frame: Baseline, Week 9, Week 51, Week 51 Last Observation Carried Forward (LOCF)
Change From Baseline in Insulin Dose Responsiveness for Carbon Monoxide Diffusing Capacity (DLco) Measured 10 and 60 Minutes After the First Daily Dose of Insulin
Carbon Monoxide Diffusing Capacity (DLco) dose responsivness 10 and 60 minutes after insulin. DLco dose-responsiveness to insulin was defined as the difference between the DLco value following a dose of insulin and DLco value before a dose of insulin, operationally defined as the post-dose DLco value minus pre-dose DLco value.
Time frame: Baseline, Week 9, Week 51
Methacholine Challenge
Methacholine Challange: performed on a subset of subjects using the 5-breath dosimeter method. Subjects were challenged with ascending doses of nebulized methacholine; dosing schedule: 0.03, 0.06, 0.12, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0, 32.0 milligrams per milliliter (mg/ml) administered in 5-minute intervals. Forced expiratory volume in 1 second (FEV1) was measured 1-3 minutes after each inhalation of methacholine solution. Testing continued until highest FEV1 decreased by ≥20% from the challenge (post-diluent) reference, or until completion all doses.
Time frame: 1 to 2 days following Weeks -3 and -1 visits, and at Week 11, Week 50, and Week 52 (+5)
Mean Weekly Morning and Evening Peak Expiratory Flow Rate (PEFR) and Forced Expiratory Volume in 1 Second (FEV1)
Subjects measured peak expiratory flow rate (PEFR) and forced expiratory volume in 1 second (FEV1) twice daily and entered the results in an electronic diary. Daily data were used to calculate the mean PEFR and FEV1 for each week (observed weekly mean and change from baseline in weekly mean). For each subject, the mean weekly morning (and evening) PEFR and FEV1 was defined as the sum of the daily morning (and evening) PEFR (and FEV1) measurements during the week divided by the number of non-missing PEFR (and FEV1) measurements during the week.
Time frame: Week -3 through Week 52
Mean Weekly Number of Puffs of Albuterol Used (Rescue Medication)
All subjects used an electronic symptom diary to record their daily use of short-acting bronchodilators. Subjects recorded the sum of their short-acting bronchodilator use (puffs of albuterol) daily, immediately upon arising, and again in the evening or before bed.
Time frame: Daily: Baseline to end of study
Number of Subjects With Step-up and Step-down Changes in Classification of Asthma Severity by Medication Usage
All asthma medication changes during the study were classified as step-up or step-down according to treatment guidelines. Step 1: Intermittant Asthma; Step 2: Mild Persistent Asthma; Step 3: Moderate Persistent Asthma; Step 4: Severe Persistent Asthma. The number of subjects in each step classification of asthma severity were provided at each assessment timepoint for each treatment group, with a shift table indicating the number of subjects moving from each step classification at each timepoint.
Time frame: Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52, Week 54, Week 58
Step Classification of Asthma Severity by Medication Usage
Step classification of asthma severity by medication usage. Subjects were classified at each visit according to the medication used on the day of the particular time-point; Step 1: intermittent asthma, Step 2: mild persistent asthma, Step 3: moderate persistent asthma, Step 4: severe persistent asthma. The number (%) of subjects in each step classification were provided at each assessment timepoint with a shift table indicating the number (%) of subjects moving from each step classification at each time-point.
Time frame: Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52, Week 54, Week 58
Mean Weekly Asthma Symptom Scores
Mean weekly asthma symptom scores: subjects recorded their asthma symptom scores in an electronic symptom diary twice daily throughout the study, immediately upon awakening (5-10 AM) and in the evening or at bedtime (7-12 PM). Questions included extent of albuterol use, symptoms of wheezing, coughing, activity limitations and sleep; scale 0 (none/fine) to 3 (severe/ continuous/bad night).
Time frame: Baseline through end of study
Incidence of Non-severe Asthma Exacerbations
Non-severe asthma exacerbation = one of the following: any home monitored morning (4:45 am - 10:15 am) forced expiratory volume in 1 second (FEV1) \<80% of the morning baseline for 2 or more consecutive days; or home monitored FEV1 \<60% of Baseline at any time. Percent of Baseline = 100\*(daily FEV1)/Baseline weekly FEV1. Subject-months=elapsed number of months a subject was in the study in each time interval. Crude event rate = total events divided by subject-months.
Time frame: 0 to 1 week to > 12 months
Incidence of Severe Asthma Exacerbations
Severe asthma exacerbation was defined as one of the following: subject received oral (systemic) corticosteriods for the treatment of asthma; or subject had an unscheduled visit to a physician, emergency room, or hospital for the treatment of asthma. Subject-months=elapsed number of months a subject was in the study in each time interval. Crude event rate = total events divided by subject-months \* 100.
Time frame: 0 to 1 Week to > 12 Months
Number of Systemic Corticosteroid Rescues
Number of subjects who used a systemic corticosteroid at any time during the study, and the total number of systemic corticosteroid rescues. New rescue event = \>=2 consecutive days between the end of one event and the start of another event.
Time frame: Baseline through Week 52
Asthma Control as Measured by the Asthma Control Questionnaire©
Asthma Control Questionnaire©: 6 self-administered questions that assess asthma control over the past week covering nocturnal waking, morning symptoms, activity limitations, shortness of breath, wheezing, and short-acting bronchodilator use; 7-point ordinal rating scale from 0 (good control) to 6 (poor control). A seventh question was completed by a health professional on forced expiratory volume in 1 second (FEV1) % predicted using a one-week recall period; scale: 0 (\>95% predicted) to 6 (\<50% predicted). Overall score = mean of questions 1 - 7.
Time frame: Baseline, Weeks 4, 12, 26, 39, 52
Baseline Dyspnea Index (BDI)
Total score = the sum of the numeric grades from the three dyspnea index questions. Functional Impairment rating scale: Grade 4 (no impairment) to Grade 0 (very severe impairment); Magnitude of Task rating scale: Grade 4 (extraordinary) to Grade 0 (no task); and Magnitude of Effort rating scale: Grade 4 (extraordinary) to grade 0 (no effort).
Time frame: run-in period
Transition Dyspnea Index (TDI): Change in Total Score
Transition Dyspnea Index total score = sum of the numeric grades from the three dyspnea index questions: Change in Functional Impairment, Change in Magnitude of Task, and Change in Magnitude of Effort. Rating scale: -3 (major deterioration), -2 (moderate deterioration), -1 (minor deterioration, 0 (no change), +1 (minor improvement), +2 (moderate improvement), +3 (major improvement).
Time frame: Week 4, Week 12, Week 26, Week 39, Week 52
Glycosylated Hemoglobin (HbA1c)
Glycosylated Hemoglobin (HbA1c): observed mean values at Baseline and each observation, and change from Baseline. Change from Baseline = mean HbA1c at observation minus mean HbA1c at Baseline.
Time frame: Baseline, Week 6, Week 12, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Fasting Plasma Glucose
Fasting plasma glucose (milligrams per deciliter \[mg/dL\]) at Baseline, and change from Baseline. Change from baseline: mean of value of fasting plasma glucose in mg/dL at observation minus baseline value.
Time frame: Baseline, Week 6, Week 12, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Body Weight: Mean Baseline and Change From Baseline
Body weight: mean Baseline and change from Baseline in kilograms (kg). Change from baseline = mean body weight in kilograms (kg) at observation minus baseline value.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 11, Week 12, Week 18, Wek 26, Week 39, Week 50, Week 51, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Total Daily Long-Acting Insulin Dose (Unadjusted for Body Weight)
Total Daily Long-Acting Insulin Dose Unadjusted for Body Weight: long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups. Inhaled Insulin reported in mg. Subcutaneous Insulin reported in units.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52
Total Daily Long-Acting Insulin Dose Adjusted for Body Weight
Total daily dose of long-acting insulin adjusted for body weight (units per kilogram \[kg\]). Long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups. Inhaled Insulin reported in mg/kg. Subcutaneous Insulin reported in units/kg.
Time frame: Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52
Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)
Average Total Daily Insulin Dose: short-acting insulin (milligrams \[mg\]). Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.
Time frame: Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52
Total Daily Short-Acting Insulin Dose Adjusted for Body Weight
Total Daily Short-Acting Insulin Dose adjusted for body weight (units divided by kg). Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.
Time frame: Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52
Lipids: Median Change From Baseline to Last Observation
Lipids: median changes (milligrams per deciliter \[mg/dL\]) from Baseline median to last observation in cholesterol (random), triglycerides (random), high density lipoprotein (HDL) cholesterol and low density lipoprotein (LDL) cholesterol. Normalized data was used in the computations. Last observation = last observation while on study drug or during the lag. Measures of dispersion for median changes in lipids were not determined.
Time frame: Baseline to Last Observation
Hypoglycemic Event Rates
A Hypoglycemic event was identified by characteristic symptoms of hypoglycemia with no blood glucose check with prompt resolution with food intake, subcutaneous glucagon, or intravenouus glucose; characteristic symptoms with blood glucose of 59 milligrams per deciliter (mg/dL) (3.2 mmol/L) or less with blood glucose check; or any glucose measurement of 49 mg/dL (2.7 mmol/L) or less, with or without symptoms. Crude event rate = total events divided by subject months. Subject months = elapsed number of months a subject was in the study in each time interval.
Time frame: 0 to 1 month to 11 to 12 months, and Overall
Severe Hypoglycemic Event Rates
Severe hypoglycemic event = all 3 of the following criteria were met: subject unable to treat self, exhbited at least 1 neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, loss of consciousness); blood glucose measurement was ≤ 49 mg/dL, or not measured but clinical manifestations reversed by oral carbohydrates, subcutaneous glucagon, or i.v. glucose. Crude event rate = number of events divided by 100 subject-months. Subject months = elapsed number of months subject was in study in each time interval.
Time frame: 0 to 1 month to 11 to 12 months, and Overall
Subjects were recruited at 63 centers and participated in the study between 10 January 2003 and 22 October 2008.
| Milestone | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Started | 146 | 141 |
| Completed | 106 | 123 |
| Not completed | 40 | 18 |
| Withdrew: Adverse event | 12 | 1 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Lost to follow-up | 7 | 3 |
| Withdrew: Reason not specified | 6 | 3 |
| Withdrew: Withdrawal by subject | 14 | 10 |
Annualized rates of change (slope throughout time from baseline to end of study\[visit\]) for forced expiratory volume in 1 second (FEV1) (liters per year \[L/yr\]) measured 30 minutes following the administration of albuterol.
| L/yr | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Annualized Rate of Change for Forced Expiratory Volume in 1 Second (FEV1) | -0.070 ± 0.020 | -0.035 ± 0.019 |
Change from Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) at each visit. FEV1 was measured in liters (L) before the administration of albuterol. Change from baseline: mean FEV1 (L) at observation minus mean baseline value.
| liters | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (141, 139) | 2.435 ± 0.748 | 2.412 ± 0.727 |
| Week 1 (123, 125) | -0.057 ± 0.142 | -0.035 ± 0.131 |
| Week 2 (n=127, 117) | -0.065 ± 0.159 | -0.034 ± 0.150 |
| Week 3 (n=130, 121) | -0.067 ± 0.185 | -0.044 ± 0.171 |
| Week 4 (n=123, 130) | -0.076 ± 0.185 | -0.037 ± 0.181 |
| Week 6 (n=130, 135) | -0.059 ± 0.211 | -0.034 ± 0.170 |
| Week 12 (n=125, 130) | -0.067 ± 0.237 | -0.032 ± 0.193 |
| Week 18 (n=125, 125) | -0.063 ± 0.218 | -0.042 ± 0.183 |
| Week 26 (n=120, 129) | -0.058 ± 0.190 | -0.043 ± 0.195 |
| Week 39 (n=108, 124) | -0.076 ± 0.195 | -0.044 ± 0.186 |
| Week 52 (n=106, 112) | -0.136 ± 0.259 | -0.056 ± 0.230 |
| Week 52 LOCF (n=141, 139) | -0.119 ± 0.259 | -0.058 ± 0.222 |
Change From Baseline in Pre-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco) measured in milliters/minutes/millimeters of mercury (mL/min/mmHg): change = DLco at observation minus DLco at Baseline.
| ml/min/mmHg | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=141, 139) | 23.034 ± 5.921 | 22.911 ± 6.059 |
| Week 1 (n=123, 125) | -0.749 ± 1.467 | -0.452 ± 1.220 |
| Week 2 (n=126, 114) | -0.835 ± 1.353 | -0.456 ± 1.485 |
| Week 3 (n=128, 119) | -0.855 ± 1.407 | -0.556 ± 1.452 |
| Week 4 (n=122, 127) | -1.120 ± 1.609 | -0.648 ± 1.500 |
| Week 6 (n=129, 135) | -1.169 ± 1.583 | -0.669 ± 1.441 |
| Week 12 (n=124, 128) | -1.018 ± 1.842 | -0.725 ± 1.788 |
| Week 18 (n=123, 125) | -0.906 ± 1.756 | -0.646 ± 1.748 |
| Week 26 (n=117, 127) | -0.945 ± 1.683 | -0.561 ± 1.982 |
| Week 39 (n=106, 125) | -0.821 ± 1.742 | -0.550 ± 1.805 |
| Week 52 (n=105, 111) | -1.699 ± 2.157 | -0.911 ± 2.239 |
| Week 52 LOCF (n=141, 139) | -1.557 ± 2.109 | -0.785 ± 2.141 |
Change from Baseline in Pre-Insulin Forced Expiratory Volume in one second (FEV1) measured in liters (L): change = FEV1 at observation minus FEV1 at Baseline.
| liters | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=130, 133) | 2.449 ± 0.775 | 2.403 ± 0.727 |
| Week 9 (n=111, 108) | -0.038 ± 0.235 | -0.028 ± 0.163 |
| Week 51 (n=103, 119) | -0.078 ± 0.227 | -0.017 ± 0.245 |
| Week 51 LOCF (n=130, 133) | -0.068 ± 0.237 | -0.018 ± 0.237 |
Change From Baseline in Pre-Insulin Carbon Monoxide Diffusing Capacity (DLco) measured in milliters/minutes/millimeters of mercury (mL/min/mmHg): change = DLco at observation minus DLco at Baseline.
| ml/min/mmHg | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=128, 131) | 22.836 ± 6.087 | 22.718 ± 6.128 |
| Week 9 (n=109, 106) | -1.130 ± 1.663 | -0.663 ± 1.549 |
| Week 51 (n=102, 116) | -1.156 ± 1.825 | -0.630 ± 2.023 |
| Week 51 LOCF (n=128, 131) | -1.185 ± 1.804 | -0.533 ± 1.990 |
Change from baseline in Post-bronchodilator Forced Vital Capacity (FVC) measured in liters (L) 30 minutes following the administration of albuterol: change = FVC at observation minus FVC at Baseline.
| liters | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=141, 139) | 3.355 ± 0.963 | 3.341 ± 0.918 |
| Week 1 (n=123, 125) | -0.068 ± 0.181 | -0.046 ± 0.134 |
| Week 2 (n=126, 115) | -0.057 ± 0.190 | -0.053 ± 0.169 |
| Week 3 (n=131, 119) | -0.078 ± 0.205 | -0.068 ± 0.174 |
| Week 4 (n=121, 129) | -0.065 ± 0.193 | -0.051 ± 0.176 |
| Week 6 (n=130, 135) | -0.092 ± 0.287 | -0.043 ± 0.173 |
| Week 12 (n=125, 129) | -0.045 ± 0.222 | -0.056 ± 0.190 |
| Week 18 (n=124, 125) | -0.053 ± 0.225 | -0.069 ± 0.179 |
| Week 26 (n=120, 128) | -0.061 ± 0.215 | -0.052 ± 0.186 |
| Week 39 (n=107, 124) | -0.080 ± 0.209 | -0.057 ± 0.213 |
| Week 52 (n=106, 112) | -0.105 ± 0.288 | -0.088 ± 0.259 |
| Week 52 LOCF (n=141, 139) | -0.097 ± 0.278 | -0.083 ± 0.247 |
Responsiveness was the percent change from the forced expiratory volume in 1 second (FEV1) value before bronchodilator use to the FEV1 value 30 minutes after bronchodilator use, operationally defined as \[(post-bronchodilator FEV1 minus pre-bronchodilator FEV1 divided by pre-bronchodilator FEV1\] multiplied by 100.
| percent change in FEV1 | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=141, 139) | 5.487 ± 5.163 | 5.102 ± 6.416 |
| Week 1 (n=123, 125) | -0.015 ± 5.452 | 0.347 ± 5.429 |
| Week 2 (n=126, 115) | 0.683 ± 5.984 | 0.347 ± 6.354 |
| Week 3 (n=130, 119) | -0.055 ± 6.082 | 0.823 ± 5.449 |
| Week 4 (n=121, 129) | 0.056 ± 6.361 | 0.559 ± 5.733 |
| Week 6 (n=130, 135) | -0.460 ± 5.480 | 0.504 ± 6.350 |
| Week 12 (n=124, 129) | 0.721 ± 5.972 | -0.100 ± 6.783 |
| Week 18 (n=124, 125) | -0.095 ± 5.909 | 0.154 ± 7.649 |
| Week 26 (n=120, 128) | -0.186 ± 5.624 | 0.211 ± 5.080 |
| Week 39 (n=107, 124) | -0.283 ± 5.368 | 0.133 ± 5.089 |
| Week 52 (n=106, 112) | 0.640 ± 5.338 | -0.035 ± 6.156 |
Percent predicted change from Baseline in post-bronchodilator forced expiratory volume in one second (FEV1) measured in liters (L): National Health and Nutrition Examination Survey (NHANES III) reference standard. Percent change from Baseline in post-bronchdilator FEV1 measured in liters (L): (observed value minus Baseline value) divided by Baseline value \*100%.
| percentage of FEV1 | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=141, 139) | 83.698 ± 14.096 | 82.833 ± 15.219 |
| Week 1: % of Predicted Value (n=123, 125) | 81.987 ± 14.441 | 82.878 ± 15.438 |
| Week 2: % of Predicted Value (n=126, 115) | 81.655 ± 13.985 | 81.881 ± 15.017 |
| Week 3: % of Predicted Value (n=131, 119) | 80.711 ± 13.854 | 82.036 ± 15.354 |
| Week 4: % of Predicted Value (n=121, 129) | 81.093 ± 15.145 | 82.029 ± 14.914 |
| Week 6: % of Predicted Value (n=130, 135) | 81.611 ± 14.553 | 82.016 ± 15.509 |
| Week 12: % of Predicted Value (n=125, 129) | 82.145 ± 13.885 | 81.640 ± 14.673 |
| Week 18: % of Predicted Value (n=124, 125) | 82.187 ± 14.405 | 81.723 ± 14.505 |
| Week 26: % of Predicted Value (n=120, 128) | 82.941 ± 14.291 | 82.227 ± 14.305 |
| Week 39: % of Predicted Value (n=107, 124) | 82.851 ± 14.447 | 81.847 ± 14.794 |
| Week 52: % of Predicted Value (n=106, 112) | 80.869 ± 14.934 | 81.138 ± 14.461 |
| Week 52 LOCF: % of Predicted Value (n=141, 139) | 80.136 ± 14.528 | 80.687 ± 14.671 |
| Week 1: % Change from Baseline (n=123, 125) | -2.682 ± 5.780 | -1.238 ± 5.307 |
| Week 2: % Change from Baseline (n=126, 115) | -2.355 ± 5.909 | -1.142 ± 5.273 |
| Week 3: % Change from Baseline (n=131, 119) | -2.943 ± 7.583 | -1.057 ± 5.292 |
| Week 4: % Change from Baseline (n=121, 129) | -3.063 ± 6.926 | -0.833 ± 6.172 |
| Week 6: % Change from Baseline (n=130, 135) | -2.559 ± 8.725 | -0.957 ± 6.180 |
| Week 12: % Change from Baseline (n=125, 129) | -1.975 ± 8.495 | -1.226 ± 7.603 |
| Week 18: % Change from Baseline (n=124, 125) | -2.437 ± 8.713 | -1.247 ± 6.688 |
| Week 26: % Change from Baseline (n=120, 128) | -2.006 ± 6.891 | -1.189 ± 8.013 |
| Week 39: % Change from Baseline (n=107, 124) | -3.144 ± 7.507 | -1.466 ± 8.332 |
| Week 52: % Change from Baseline (n=106, 112) | -4.777 ± 8.794 | -2.002 ± 10.040 |
| Week 52 LOCF: % Change from Baseline (n=141, 139) | -4.129 ± 9.673 | -2.108 ± 9.652 |
Change from Baseline in Insulin Dose Responsiveness for Forced Expiratory Volume in one second (FEV1) measured 10 and 60 minutes after the first daily dose of insulin. Insulin dose responsiveness = the difference between FEV1 value following a dose of insulin and FEV1 value before a dose of insulin, operationally defined as the post dose FEV1 value minus predose FEV1 value.
| liters | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline: 10 minutes (n=124, 131) | -0.004 ± 0.085 | 0.003 ± 0.086 |
| Week 9: 10 minutes (n=105, 106) | -0.008 ± 0.130 | 0.005 ± 0.111 |
| Week 51: 10 minutes (n=96, 113) | 0.000 ± 0.113 | 0.013 ± 0.104 |
| Baseline: 60 minutes (n=125, 131) | -0.004 ± 0.120 | 0.016 ± 0.130 |
| Week 9: 60 minutes (n=105, 105) | 0.013 ± 0.113 | 0.028 ± 0.137 |
| Week 51: 60 minutes (n=99, 112) | 0.029 ± 0.139 | 0.020 ± 0.123 |
Percent predicted change from Baseline in 10 Minute and 60 Minute post-insulin forced expiratory volume in one second (FEV1) measured in liters (L): National Health and Nutrition Examination Survey (NHANES III) reference standard. Percent change from Baseline in FEV1 measured in liters (L) 10 and 60 Minutes post-insulin. Percent change = (value at observation minus Baseline value) divided by Baseline value \*100%.
| percent | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline: 10 minutes (n=124, 131) | 94.402 ± 6.532 | 94.391 ± 6.168 |
| Week 9: 10 min.; % of Predicted Value (n=105, 106) | 92.698 ± 9.187 | 94.190 ± 7.190 |
| Week 9: 10 min;% Change from Baseline (n=105, 106) | -1.864 ± 9.684 | -0.456 ± 8.638 |
| Week 51: 10 min.;% of Predicted Value (n=96, 113) | 91.668 ± 8.223 | 93.717 ± 9.305 |
| Week 51:10 min;% Change from Baseline (n=96, 113) | -2.760 ± 8.789 | 0.228 ± 13.653 |
| Week 51 LOCF:10 min;% Predicted Value (n=124, 131) | 91.196 ± 8.366 | 93.882 ± 9.013 |
| Week 51 LOCF:10 min;% Change from BL (n=124, 131) | -3.176 ± 8.825 | -0.029 ± 12.946 |
| Baseline: 60 minutes (n=125, 131) | 94.284 ± 6.548 | 94.688 ± 5.260 |
| Week 9: 60 min.; % of Predicted Value (n=105, 105) | 93.586 ± 8.219 | 94.950 ± 7.526 |
| Week 9: 60 min;% Change from Baseline (n=105, 105) | -0.450 ± 9.464 | -0.031 ± 7.497 |
| Week 51: 60 min.; % of Predicted Value (n=99, 112) | 92.302 ± 7.949 | 94.084 ± 9.069 |
| Week 51:60 min.;% Change from Baseline (n=99, 112) | -1.699 ± 9.015 | -0.247 ± 10.349 |
| Week 51 LOCF:60 min;% Predicted Value (n=125, 131) | 92.418 ± 8.544 | 94.300 ± 8.823 |
| Week 51 LOCF:60 min;% Change from BL (n=125, 131) | -1.714 ± 9.512 | -0.222 ± 9.816 |
Carbon Monoxide Diffusing Capacity (DLco) dose responsivness 10 and 60 minutes after insulin. DLco dose-responsiveness to insulin was defined as the difference between the DLco value following a dose of insulin and DLco value before a dose of insulin, operationally defined as the post-dose DLco value minus pre-dose DLco value.
| ml/min/mmHg | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline: 10 minutes (n=122, 129) | -0.163 ± 0.992 | -0.184 ± 0.985 |
| Week 9: 10 minutes (n=102, 104) | -0.241 ± 1.390 | -0.131 ± 1.006 |
| Week 51: 10 minutes (n=95, 109) | -0.139 ± 0.893 | -0.171 ± 0.820 |
| Baseline: 60 minutes (n=135, 133) | -0.446 ± 1.115 | -0.451 ± 1.258 |
| Week 9: 60 minutes (n=104, 108) | -0.338 ± 1.416 | -0.159 ± 1.126 |
| Week 51: 60 minutes (n=101, 110) | -0.216 ± 1.458 | -0.383 ± 1.030 |
Methacholine Challange: performed on a subset of subjects using the 5-breath dosimeter method. Subjects were challenged with ascending doses of nebulized methacholine; dosing schedule: 0.03, 0.06, 0.12, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0, 32.0 milligrams per milliliter (mg/ml) administered in 5-minute intervals. Forced expiratory volume in 1 second (FEV1) was measured 1-3 minutes after each inhalation of methacholine solution. Testing continued until highest FEV1 decreased by ≥20% from the challenge (post-diluent) reference, or until completion all doses.
No measurements were reported for this outcome.
Subjects measured peak expiratory flow rate (PEFR) and forced expiratory volume in 1 second (FEV1) twice daily and entered the results in an electronic diary. Daily data were used to calculate the mean PEFR and FEV1 for each week (observed weekly mean and change from baseline in weekly mean). For each subject, the mean weekly morning (and evening) PEFR and FEV1 was defined as the sum of the daily morning (and evening) PEFR (and FEV1) measurements during the week divided by the number of non-missing PEFR (and FEV1) measurements during the week.
No measurements were reported for this outcome.
All subjects used an electronic symptom diary to record their daily use of short-acting bronchodilators. Subjects recorded the sum of their short-acting bronchodilator use (puffs of albuterol) daily, immediately upon arising, and again in the evening or before bed.
No measurements were reported for this outcome.
All asthma medication changes during the study were classified as step-up or step-down according to treatment guidelines. Step 1: Intermittant Asthma; Step 2: Mild Persistent Asthma; Step 3: Moderate Persistent Asthma; Step 4: Severe Persistent Asthma. The number of subjects in each step classification of asthma severity were provided at each assessment timepoint for each treatment group, with a shift table indicating the number of subjects moving from each step classification at each timepoint.
No measurements were reported for this outcome.
Step classification of asthma severity by medication usage. Subjects were classified at each visit according to the medication used on the day of the particular time-point; Step 1: intermittent asthma, Step 2: mild persistent asthma, Step 3: moderate persistent asthma, Step 4: severe persistent asthma. The number (%) of subjects in each step classification were provided at each assessment timepoint with a shift table indicating the number (%) of subjects moving from each step classification at each time-point.
No measurements were reported for this outcome.
Mean weekly asthma symptom scores: subjects recorded their asthma symptom scores in an electronic symptom diary twice daily throughout the study, immediately upon awakening (5-10 AM) and in the evening or at bedtime (7-12 PM). Questions included extent of albuterol use, symptoms of wheezing, coughing, activity limitations and sleep; scale 0 (none/fine) to 3 (severe/ continuous/bad night).
No measurements were reported for this outcome.
Non-severe asthma exacerbation = one of the following: any home monitored morning (4:45 am - 10:15 am) forced expiratory volume in 1 second (FEV1) \<80% of the morning baseline for 2 or more consecutive days; or home monitored FEV1 \<60% of Baseline at any time. Percent of Baseline = 100\*(daily FEV1)/Baseline weekly FEV1. Subject-months=elapsed number of months a subject was in the study in each time interval. Crude event rate = total events divided by subject-months.
| events/subject-months | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| 0 to 1 Week (n=141, 139) | 0.43 | 0.41 |
| >1 to 2 Weeks (n=141, 139) | 0.28 | 0.38 |
| >2 to 3 Weeks (n=141, 139) | 0.22 | 0.31 |
| >3 to 4 Weeks (n=141, 139) | 0.37 | 0.41 |
| >4 to 6 Weeks (n=141, 139) | 0.52 | 0.36 |
| >6 to 9 Weeks (n=138, 139) | 0.53 | 0.51 |
| >9 to 12 Weeks (n=134, 138) | 0.35 | 0.46 |
| >3 Months (n=133, 137) | 0.40 | 0.40 |
| >6 to 9 Months (n=121, 133) | 0.30 | 0.49 |
| >9 to 12 Months (n=114, 131) | 0.27 | 0.43 |
| >12 Months (n=67, 81) | 0.34 | 0.21 |
| Overall (n=141, 139) | 0.35 | 0.43 |
Severe asthma exacerbation was defined as one of the following: subject received oral (systemic) corticosteriods for the treatment of asthma; or subject had an unscheduled visit to a physician, emergency room, or hospital for the treatment of asthma. Subject-months=elapsed number of months a subject was in the study in each time interval. Crude event rate = total events divided by subject-months \* 100.
| events/subject months*100 | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| 0 to 1 Week (n=141, 139) | 0.00 | 0.00 |
| >1 to 2 Weeks (n=141, 139) | 0.00 | 3.13 |
| >2 to 3 Weeks (n=141, 139) | 0.00 | 9.39 |
| >3 to 4 Weeks (n=141, 139) | 3.08 | 0.00 |
| >4 to 6 Weeks (n=141, 139) | 4.63 | 1.56 |
| >6 to 9 Weeks (n=138, 139) | 1.06 | 0.00 |
| >9 to 12 Weeks (n=134, 138) | 1.09 | 0.00 |
| >3 Months (n=133, 137) | 1.20 | 2.27 |
| >6 to 9 Months (n=121, 133) | 1.43 | 1.01 |
| >9 to 12 Months (n=114, 131) | 1.53 | 1.33 |
| >12 Months (n=67, 81) | 3.39 | 0.00 |
| Overall (n=141, 139) | 1.46 | 1.47 |
Number of subjects who used a systemic corticosteroid at any time during the study, and the total number of systemic corticosteroid rescues. New rescue event = \>=2 consecutive days between the end of one event and the start of another event.
| systemic corticosteriod rescues | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Number of Systemic Corticosteroid Rescues | 14 | 16 |
Annualized rates of change (slope throughout time from baseline to end of study\[visit\]) for hemoglobin-adjusted carbon monoxide diffusion capacity (DLco)in milliliters per minute/millimeters of mercury/year (ml/min/mmHg/yr) measured 30 minutes following the administration of albuterol.
| ml/min/mmHg/yr | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Annualized Rate of Change for Hemoglobin-adjusted Carbon Monoxide Diffusion Capacity (DLco) | -0.776 ± 0.152 | -0.273 ± 0.153 |
Asthma Control Questionnaire©: 6 self-administered questions that assess asthma control over the past week covering nocturnal waking, morning symptoms, activity limitations, shortness of breath, wheezing, and short-acting bronchodilator use; 7-point ordinal rating scale from 0 (good control) to 6 (poor control). A seventh question was completed by a health professional on forced expiratory volume in 1 second (FEV1) % predicted using a one-week recall period; scale: 0 (\>95% predicted) to 6 (\<50% predicted). Overall score = mean of questions 1 - 7.
| scores on scale | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline: Subject Evaluation (n=138, 138) | 1.04 ± 0.78 | 1.21 ± 0.91 |
| Baseline: Clinical Evaluation (n=138, 138) | 2.50 ± 1.50 | 2.54 ± 1.70 |
| Baseline: Overall Evaluation (n=138, 138) | 1.25 ± 0.74 | 1.40 ± 0.86 |
| Week 4: Subject Evaluation (n=123, 121) | 1.08 ± 0.81 | 1.15 ± 0.89 |
| Week 4: Clinical Evaluation (n=123, 121) | 2.68 ± 1.52 | 2.65 ± 1.61 |
| Week 4: Overall Evaluation (n=123, 121) | 1.31 ± 0.78 | 1.36 ± 0.81 |
| Week 12: Subject Evaluation (n=129, 134) | 1.04 ± 0.83 | 1.17 ± 0.91 |
| Week 12: Clinical Evaluation (n=129, 134) | 2.55 ± 1.50 | 2.61 ± 1.48 |
| Week 12: Overall Evaluation (n=129, 134) | 1.25 ± 0.77 | 1.37 ± 0.83 |
| Week 26: Subject Evaluation (n=121, 131) | 1.06 ± 0.80 | 1.07 ± 0.91 |
| Week 26: Clinical Evaluation (n=121, 131) | 2.48 ± 1.43 | 2.61 ± 1.57 |
| Week 26: Overall Evaluation (n=121, 131) | 1.27 ± 0.74 | 1.29 ± 0.85 |
| Week 39: Subject Evaluation (n=110, 125) | 0.94 ± 0.76 | 1.00 ± 0.85 |
| Week 39: Clinical Evaluation (n=110, 125) | 2.54 ± 1.43 | 2.63 ± 1.52 |
| Week 39: Overall Evaluation (n=110, 125) | 1.17 ± 0.71 | 1.23 ± 0.81 |
| Week 52: Subject Evaluation (n=107, 120) | 1.08 ± 1.07 | 0.98 ± 0.84 |
| Week 52: Clinical Evaluation (n=107, 120) | 2.77 ± 1.54 | 2.64 ± 1.56 |
| Week 52: Overall Evaluation (n=107, 120) | 1.32 ± 0.99 | 1.21 ± 0.80 |
| Week 4: Subject Eval: Change from BL (n=122, 120) | 0.02 ± 0.59 | -0.07 ± 0.59 |
| Week 4: Clinical Eval: Change from BL (n=122, 120) | 0.17 ± 0.85 | 0.14 ± 0.85 |
| Week 4: Overall Eval: Change from BL (n=122, 120) | 0.04 ± 0.55 | -0.04 ± 0.53 |
| Week 12: Subject Eval: Change from BL (n=129, 134) | -0.02 ± 0.66 | -0.04 ± 0.72 |
| Week 12 Clinical Eval: Change from BL (n=129, 134) | 0.12 ± 0.94 | 0.09 ± 0.91 |
| Week 12: Overall Eval: Change from BL (n=129, 134) | 0.00 ± 0.59 | -0.02 ± 0.62 |
| Week 26: Subject Eval: Change from BL (n=121, 130) | 0.05 ± 0.77 | -0.12 ± 0.82 |
| Week 26 Clinical Eval: Change from BL (n=121, 130) | 0.09 ± 0.78 | 0.09 ± 1.00 |
| Week 26: Overall Eval: Change from BL (n=121, 130) | 0.05 ± 0.68 | -0.09 ± 0.73 |
| Week 39: Subject Eval: Change from BL (n=110, 124) | -0.09 ± 0.65 | -0.19 ± 0.77 |
| Week 39 Clinical Eval: Change from BL (n=110, 124) | 0.14 ± 1.05 | 0.11 ± 0.94 |
| Week 39: Overall Eval: Change from BL (n=110, 124) | -0.06 ± 0.58 | -0.15 ± 0.68 |
| Week 52: Subject Eval: Change from BL (n=106, 119) | 0.06 ± 0.88 | -0.19 ± 0.86 |
| Week 52 Clinical Eval: Change from BL (n=106, 119) | 0.38 ± 0.87 | 0.10 ± 1.20 |
| Week 52: Overall Eval: Change from BL (n=106, 119) | 0.11 ± 0.77 | -0.15 ± 0.77 |
Total score = the sum of the numeric grades from the three dyspnea index questions. Functional Impairment rating scale: Grade 4 (no impairment) to Grade 0 (very severe impairment); Magnitude of Task rating scale: Grade 4 (extraordinary) to Grade 0 (no task); and Magnitude of Effort rating scale: Grade 4 (extraordinary) to grade 0 (no effort).
| scores on scale | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Functional Impairment | 3.37 ± 0.80 | 3.36 ± 0.87 |
| Magnitude of Task | 2.29 ± 1.19 | 2.29 ± 1.25 |
| Magnitude of Effort | 2.49 ± 1.39 | 2.34 ± 1.49 |
| Total Score | 8.15 ± 2.98 | 7.97 ± 2.99 |
Transition Dyspnea Index total score = sum of the numeric grades from the three dyspnea index questions: Change in Functional Impairment, Change in Magnitude of Task, and Change in Magnitude of Effort. Rating scale: -3 (major deterioration), -2 (moderate deterioration), -1 (minor deterioration, 0 (no change), +1 (minor improvement), +2 (moderate improvement), +3 (major improvement).
| scores on scale | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Week 4 (n=121, 122) | 0.36 ± 1.93 | 0.50 ± 1.92 |
| Week 12 (n=131, 135) | 0.51 ± 1.76 | 0.47 ± 1.68 |
| Week 26 (n=124, 131) | 0.14 ± 1.75 | 0.13 ± 1.55 |
| Week 39 (n=112, 127) | 0.26 ± 1.56 | 0.29 ± 1.61 |
| Week 52 (n=105, 121) | 0.13 ± 1.65 | 0.67 ± 2.01 |
Glycosylated Hemoglobin (HbA1c): observed mean values at Baseline and each observation, and change from Baseline. Change from Baseline = mean HbA1c at observation minus mean HbA1c at Baseline.
| percent | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=135, 135) | 7.62 ± 1.12 | 7.43 ± 1.08 |
| Week 6: Observed Value (n=127, 126) | 7.22 ± 1.00 | 6.97 ± 0.90 |
| Week 6: Change from Baseline (n=127, 126) | -0.38 ± 0.65 | -0.43 ± 0.49 |
| Week 12: Observed Value (n=122, 127) | 7.28 ± 1.12 | 6.98 ± 0.97 |
| Week 12: Change from Baseline (n=122, 127) | -0.32 ± 0.98 | -0.48 ± 0.69 |
| Week 26: Observed Value (n=118, 120) | 7.38 ± 1.24 | 7.19 ± 1.18 |
| Week 26: Change from Baseline (n=118, 120) | -0.12 ± 1.07 | -0.25 ± 0.93 |
| Week 39: Observed Value (n=108, 123) | 7.44 ± 1.31 | 7.20 ± 1.16 |
| Week 39: Change from Baseline (n=108, 123) | -0.08 ± 1.10 | -0.21 ± 0.91 |
| Week 52: Observed Value (n=101, 118) | 7.51 ± 1.35 | 7.35 ± 1.28 |
| Week 52: Change from Baseline (n=101, 118) | 0.00 ± 1.05 | -0.05 ± 1.01 |
| Week 52 (LOCF): Observed Value (n=135, 135) | 7.58 ± 1.35 | 7.40 ± 1.36 |
| Week 52 (LOCF): Change from Baseline (n=135, 135) | -0.04 ± 1.07 | -0.03 ± 1.04 |
Fasting plasma glucose (milligrams per deciliter \[mg/dL\]) at Baseline, and change from Baseline. Change from baseline: mean of value of fasting plasma glucose in mg/dL at observation minus baseline value.
| mg/dL | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=112, 123) | 149.22 ± 49.92 | 149.03 ± 58.33 |
| Week 6: Observed Value (n=103, 112) | 143.02 ± 68.92 | 136.54 ± 57.98 |
| Week 6: Change from Baseline (n=103, 112) | -3.34 ± 68.47 | -15.19 ± 67.16 |
| Week 12: Observed Value (n=106, 113) | 136.32 ± 63.00 | 144.47 ± 61.22 |
| Week 12: Change from Baseline (n=106, 113) | -12.16 ± 65.62 | -5.40 ± 67.71 |
| Week 26: Observed Value (n=102, 114) | 139.05 ± 64.63 | 143.54 ± 52.09 |
| Week 26: Change from Baseline (n=102, 114) | -11.86 ± 76.07 | -4.63 ± 65.10 |
| Week 39: Observed Value (n=102, 115) | 143.64 ± 63.89 | 142.91 ± 66.26 |
| Week 39: Change from Baseline (n=102, 115) | -5.67 ± 67.65 | -7.47 ± 65.55 |
| Week 52: Observed Value (n=98, 115) | 146.32 ± 66.04 | 145.43 ± 59.35 |
| Week 52: Change from Baseline (n=98, 115) | -3.86 ± 60.61 | -2.53 ± 63.23 |
| Week 52 LOCF: Observed Value (n=112, 123) | 148.28 ± 71.07 | 144.96 ± 58.80 |
| Week 52 LOCF: Change from Baseline (n=112, 123) | -0.95 ± 72.53 | -4.07 ± 62.75 |
Body weight: mean Baseline and change from Baseline in kilograms (kg). Change from baseline = mean body weight in kilograms (kg) at observation minus baseline value.
| kilograms | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=113, 124) | 87.41 ± 21.04 | 87.13 ± 17.58 |
| Week 1: Change from Baseline (n=102, 113) | -0.02 ± 1.45 | 1.00 ± 7.63 |
| Week 2: Change from Baseline (n=104, 105) | 0.12 ± 1.31 | 0.57 ± 1.50 |
| Week 3: Change from Baseline (n=103, 113) | 0.18 ± 1.64 | 0.34 ± 1.55 |
| Week 4: Change from Baseline (n=101, 119) | 0.31 ± 1.74 | 0.44 ± 1.70 |
| Week 6: Change from Baseline (n=106, 122) | 0.13 ± 1.93 | 0.68 ± 1.88 |
| Week 9: Change from Baseline (n=101, 104) | 0.14 ± 2.31 | 0.91 ± 2.33 |
| Week 11: Change from Baseline (n=14, 17) | 0.71 ± 1.77 | 0.69 ± 2.00 |
| Week 12: Change from Baseline (n=106, 118) | 0.01 ± 2.96 | 0.84 ± 2.83 |
| Week 18: Change from Baseline (n=110, 116) | 0.35 ± 3.04 | 1.27 ± 3.46 |
| Week 26: Change from Baseline (n=111, 121) | 0.72 ± 3.52 | 1.29 ± 3.32 |
| Week 39: Change from Baseline (n=107, 121) | 0.77 ± 4.33 | 1.33 ± 3.70 |
| Week 50: Change from Baseline (n=19, 13) | 0.04 ± 3.67 | 1.98 ± 3.90 |
| Week 51: Change from Baseline (n=49, 60) | 0.24 ± 3.75 | 0.63 ± 4.38 |
| Week 52: Change from Baseline (n=90, 109) | 1.34 ± 3.98 | 1.26 ± 4.08 |
| Week 52 LOCF: Change from Baseline (n=113, 124) | 1.13 ± 3.95 | 1.44 ± 4.13 |
Total Daily Long-Acting Insulin Dose Unadjusted for Body Weight: long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups. Inhaled Insulin reported in mg. Subcutaneous Insulin reported in units.
| mg, units | Inhaled Insulin (mg) | Subcutaneous Insulin (Units) |
|---|---|---|
| Baseline (n=105, 121) | 41.70 ± 24.61 | 45.50 ± 27.54 |
| Week 1 (n=104, 117) | 41.75 ± 25.75 | 45.46 ± 28.69 |
| Week 2 (n=106, 111) | 43.48 ± 26.76 | 47.19 ± 28.08 |
| Week 3 (n=104, 117) | 43.75 ± 27.32 | 47.61 ± 29.06 |
| Week 4 (n=104, 120) | 44.70 ± 28.06 | 48.54 ± 29.91 |
| Week 6 (n=106, 122) | 45.89 ± 29.31 | 48.59 ± 30.68 |
| Week 9 (n=104, 109) | 46.01 ± 30.57 | 47.68 ± 29.16 |
| Week 12 (n=110, 122) | 46.05 ± 30.82 | 49.04 ± 30.99 |
| Week 18 (n=110, 120) | 47.15 ± 32.34 | 49.94 ± 30.95 |
| Week 26 (n=111, 122) | 47.65 ± 33.87 | 49.98 ± 31.32 |
| Week 39 (n=107, 121) | 48.97 ± 33.28 | 50.32 ± 31.58 |
| Week 52 (n=101, 119) | 50.17 ± 34.17 | 50.07 ± 31.62 |
Total daily dose of long-acting insulin adjusted for body weight (units per kilogram \[kg\]). Long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups. Inhaled Insulin reported in mg/kg. Subcutaneous Insulin reported in units/kg.
| mg/kg, units/kg | Inhaled Insulin (mg/kg) | Subcutaneous Insulin (Units/kg) |
|---|---|---|
| Baseline (n=105, 121) | 0.47 ± 0.25 | 0.52 ± 0.30 |
| Week 1 (n=100, 112) | 0.47 ± 0.27 | 0.53 ± 0.31 |
| Week 2 (n=103, 104) | 0.49 ± 0.29 | 0.52 ± 0.28 |
| Week 3 (n=101, 113) | 0.49 ± 0.29 | 0.54 ± 0.31 |
| Week 4 (n=99, 118) | 0.49 ± 0.27 | 0.54 ± 0.31 |
| Week 6 (n=104, 121) | 0.52 ± 0.31 | 0.55 ± 0.32 |
| Week 9 (n=99, 103) | 0.51 ± 0.31 | 0.54 ± 0.32 |
| Week 12 (n=104, 117) | 0.52 ± 0.32 | 0.55 ± 0.32 |
| Week 18 (n=108, 115) | 0.53 ± 0.33 | 0.55 ± 0.32 |
| Week 26 (n=109, 120) | 0.52 ± 0.33 | 0.55 ± 0.32 |
| Week 39 (n=105, 120) | 0.54 ± 0.37 | 0.56 ± 0.32 |
| Week 52 (n=88, 108) | 0.53 ± 0.36 | 0.55 ± 0.31 |
Average Total Daily Insulin Dose: short-acting insulin (milligrams \[mg\]). Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.
| mg, units | Inhaled Insulin (mg) | Subcutaneous Insulin (Units) |
|---|---|---|
| Baseline (n=109, 122) | 30.56 ± 22.69 | 30.74 ± 19.50 |
| Week 1 (n=106, 118) | 11.03 ± 5.51 | 29.52 ± 19.95 |
| Week 2 (n=108, 111) | 12.13 ± 6.03 | 31.24 ± 21.69 |
| Week 3 (n=106, 116) | 12.96 ± 6.68 | 30.58 ± 20.70 |
| Week 4 (n=106, 120) | 13.44 ± 6.82 | 31.87 ± 22.23 |
| Week 6 (n=108, 122) | 14.04 ± 7.06 | 31.81 ± 21.94 |
| Week 9 (n=106, 110) | 14.03 ± 7.76 | 31.55 ± 23.93 |
| Week 12 (n=112, 122) | 14.42 ± 8.11 | 32.71 ± 23.70 |
| Week 18 (n=112, 120) | 15.11 ± 8.68 | 33.49 ± 23.81 |
| Week 26 (n=113, 122) | 15.95 ± 9.14 | 33.80 ± 24.37 |
| Week 39 (n=109, 121) | 16.17 ± 10.25 | 33.12 ± 24.62 |
| Week 52 (n= 103, 119) | 17.20 ± 10.95 | 33.04 ± 26.09 |
Total Daily Short-Acting Insulin Dose adjusted for body weight (units divided by kg). Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.
| mg/kg, units/kg | Inhaled Insulin (mg/kg) | Subcutaneous Insulin (Units/kg) |
|---|---|---|
| Baseline (n=109, 122) | 0.35 ± 0.25 | 0.36 ± 0.22 |
| Week 1 (n=102, 113) | 0.12 ± 0.06 | 0.34 ± 0.23 |
| Week 2 (n=104, 104) | 0.14 ± 0.07 | 0.36 ± 0.25 |
| Week 3 (n=103, 112) | 0.15 ± 0.07 | 0.35 ± 0.23 |
| Week 4 (n=101, 118) | 0.15 ± 0.07 | 0.37 ± 0.26 |
| Week 6 (n=106, 121) | 0.16 ± 0.08 | 0.36 ± 0.24 |
| Week 9 (n=101, 104) | 0.16 ± 0.09 | 0.36 ± 0.26 |
| Week 12 (n=106, 117) | 0.16 ± 0.08 | 0.38 ± 0.26 |
| Week 18 (n=110, 116) | 0.18 ± 0.10 | 0.37 ± 0.25 |
| Week 26 (n=111, 121) | 0.19 ± 0.11 | 0.38 ± 0.27 |
| Week 39 (n=107, 120) | 0.19 ± 0.12 | 0.38 ± 0.27 |
| Week 52 (n=90, 108) | 0.19 ± 0.12 | 0.36 ± 0.29 |
Lipids: median changes (milligrams per deciliter \[mg/dL\]) from Baseline median to last observation in cholesterol (random), triglycerides (random), high density lipoprotein (HDL) cholesterol and low density lipoprotein (LDL) cholesterol. Normalized data was used in the computations. Last observation = last observation while on study drug or during the lag. Measures of dispersion for median changes in lipids were not determined.
| mg/dL | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Cholesterol (random) (n=110, 121) | -0.5 ± -0.5 | 0 ± 0 |
| Triglycerides (random) (n=105, 121) | 9 ± 9 | -8 ± -8 |
| HDL Cholesterol (n=110, 121) | -3 ± -3 | 1 ± 1 |
| LDL Cholesterol (n=97, 110) | 0 ± 0 | 0 ± 0 |
A Hypoglycemic event was identified by characteristic symptoms of hypoglycemia with no blood glucose check with prompt resolution with food intake, subcutaneous glucagon, or intravenouus glucose; characteristic symptoms with blood glucose of 59 milligrams per deciliter (mg/dL) (3.2 mmol/L) or less with blood glucose check; or any glucose measurement of 49 mg/dL (2.7 mmol/L) or less, with or without symptoms. Crude event rate = total events divided by subject months. Subject months = elapsed number of months a subject was in the study in each time interval.
| events / subject-months | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| 0 to 1 month (n=135, 135) | 2.99 | 2.48 |
| > 1 to 2 months (n=135, 135) | 2.52 | 2.34 |
| > 2 to 3 months (n=131, 134) | 2.12 | 1.84 |
| > 3 to 4 months (n=128, 134) | 1.84 | 1.61 |
| > 4 to 5 months (n=126, 134) | 1.94 | 1.69 |
| > 5 to 6 months (n=121, 131) | 1.51 | 1.84 |
| > 6 to 7 months (n=119, 131) | 1.50 | 1.67 |
| > 7 to 8 months (n=115, 129) | 1.45 | 1.26 |
| > 8 to 9 months (n=111, 129) | 1.62 | 1.26 |
| > 9 to 10 months (n=110, 129) | 1.26 | 1.55 |
| > 10 to 11 months (n=109, 125) | 1.12 | 1.37 |
| > 11 to 12 months (n=104, 123) | 1.18 | 1.23 |
| Overall (n=135, 135) | 1.79 | 1.68 |
Severe hypoglycemic event = all 3 of the following criteria were met: subject unable to treat self, exhbited at least 1 neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, loss of consciousness); blood glucose measurement was ≤ 49 mg/dL, or not measured but clinical manifestations reversed by oral carbohydrates, subcutaneous glucagon, or i.v. glucose. Crude event rate = number of events divided by 100 subject-months. Subject months = elapsed number of months subject was in study in each time interval.
| Number of events/100 subject-months. | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| 0 to 1 month (n=135, 135) | 2.91 | 1.48 |
| > 1 to 2 months (n=135, 135) | 5.22 | 1.49 |
| > 2 to 3 months (n=131, 134) | 4.64 | 2.99 |
| > 3 to 4 months (n=128, 134) | 0.78 | 2.24 |
| > 4 to 5 months (n=126, 134) | 4.05 | 1.51 |
| > 5 to 6 months (n=121, 131) | 3.33 | 2.29 |
| > 6 to 7 months (n=119, 131) | 0.00 | 0.77 |
| > 7 to 8 months (n=115, 129) | 0.89 | 2.33 |
| > 8 to 9 months (n=111, 129) | 5.42 | 1.55 |
| > 9 to 10 months (n=110, 129) | 0.91 | 3.18 |
| > 10 to 11 months (n=109, 125) | 1.88 | 2.41 |
| > 11 to 12 months (n=104, 123) | 3.95 | 3.10 |
| Overall (n=135, 135) | 2.89 | 2.13 |
Change from Baseline at each visit in post-bronchodilator forced expiratory volume in one second (FEV1). FEV1 was measured in liters (L) 30 minutes following the administration of albuterol. Change from baseline: mean FEV1 (L) at observation minus baseline value.
| liters | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=141, 139) | 2.559 ± 0.771 | 2.524 ± 0.742 |
| Week 1 (n=123, 125) | -0.066 ± 0.150 | -0.027 ± 0.126 |
| Week 2 (n=126, 115) | -0.056 ± 0.150 | -0.031 ± 0.128 |
| Week 3 (n=131, 119) | -0.077 ± 0.185 | -0.030 ± 0.130 |
| Week 4 (n=121, 129) | -0.074 ± 0.161 | -0.022 ± 0.155 |
| Week 6 (n=130, 135) | -0.070 ± 0.248 | -0.025 ± 0.146 |
| Week 12 (n=125, 129) | -0.053 ± 0.212 | -0.031 ± 0.182 |
| Week 18 (n=124, 125) | -0.066 ± 0.226 | -0.040 ± 0.165 |
| Week 26 (n=120, 128) | -0.056 ± 0.175 | -0.038 ± 0.184 |
| Week 39 (n=107, 124) | -0.088 ± 0.191 | -0.039 ± 0.194 |
| Week 52 (n=106, 112) | -0.131 ± 0.259 | -0.059 ± 0.234 |
| Week 52 LOCF (n=141, 139) | -0.113 ± 0.261 | -0.062 ± 0.225 |
Carbon Monoxide Diffusing Capacity (DLco) measured in milliters/minutes/millimeters of mercury (mL/min/mmHg) 30 minutes following the administration of albuterol. Change from Baseline: mean DLco (mL/min/mmHg) at observation minus baseline value.
| mL/min/mmHg | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=141, 139) | 23.023 ± 5.914 | 22.883 ± 6.079 |
| Week 1 (n=122, 124) | -0.574 ± 1.392 | -0.333 ± 1.405 |
| Week 2 (n=126, 112) | -0.777 ± 1.631 | -0.481 ± 1.290 |
| Week 3 (n=129, 118) | -0.811 ± 1.244 | -0.506 ± 1.388 |
| Week 4 (n=120, 128) | -1.075 ± 1.425 | -0.576 ± 1.397 |
| Week 6 (n=129, 135) | -1.017 ± 1.633 | -0.602 ± 1.488 |
| Week 12 (n=125, 125) | -0.961 ± 1.738 | -0.477 ± 1.588 |
| Week 18 (n=124, 123) | -1.024 ± 1.774 | -0.549 ± 1.601 |
| Week 26 (n=119, 127) | -0.849 ± 1.914 | -0.477 ± 1.706 |
| Week 39 (n=107, 123) | -1.016 ± 1.649 | -0.395 ± 1.767 |
| Week 52 (n=105, 110) | -1.483 ± 1.944 | -0.798 ± 1.967 |
| Week 52 LOCF (n=141, 139) | -1.426 ± 1.856 | -0.682 ± 1.958 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inhaled Insulin | — | 21/146 (14.4%) | 140/146 (95.9%) |
| Subcutaneous Insulin | — | 13/141 (9.2%) | 136/141 (96.5%) |
| Event | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 3/146 | 0/141 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 3/146 | 2/141 |
| Acute coronary syndromeCardiac disorders | 0/146 | 2/141 |
| Chest painGeneral disorders | 2/146 | 1/141 |
| Atrial fibrillationCardiac disorders | 0/146 | 1/141 |
| Atrial flutterCardiac disorders | 0/146 | 1/141 |
| Myocardial infarctionCardiac disorders | 0/146 | 1/141 |
| Abdominal wall abscessInfections and infestations | 0/146 | 1/141 |
| PneumoniaInfections and infestations | 0/146 | 1/141 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/146 | 1/141 |
| Event | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 109/146 | 120/141 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 53/146 | 63/141 |
| Upper respiratory tract infectionInfections and infestations | 44/146 | 39/141 |
| NasopharyngitisInfections and infestations | 29/146 | 26/141 |
| CoughRespiratory, thoracic and mediastinal disorders | 29/146 | 11/141 |
| InfluenzaInfections and infestations | 20/146 | 25/141 |
| BronchitisInfections and infestations | 24/146 | 18/141 |
| SinusitisInfections and infestations | 14/146 | 21/141 |
| Urinary tract infectionInfections and infestations | 18/146 | 20/141 |
| TremorNervous system disorders | 8/146 | 17/141 |
| Age, Customized(participants) | Inhaled Insulin | Subcutaneous Insulin | Total |
|---|---|---|---|
| 18-25 years | 12 | 8 | 20 |
| 26-35 years | 18 | 13 | 31 |
| 36-45 years | 23 | 25 | 48 |
| 46-55 years | 33 | 41 | 74 |
| 56-65 years | 40 | 37 | 77 |
| 66-75 years | 20 | 17 | 37 |
| Sex: Female, Male(Participants) | Inhaled Insulin | Subcutaneous Insulin | Total |
|---|---|---|---|
| Female | 97 | 91 | 188 |
| Male | 49 | 50 | 99 |
Showing the first 100 of 102 sites across 5 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2003, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2010, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin